Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Aquestive Therapeutics, Inc. (AQST)

Aquestive investor deck: $90.3 million cash, $95 million contingent on FDA approval

Neutral Impact 2 of 5 other Written later

Aquestive Therapeutics furnished a November 2026 corporate presentation under Regulation FD, with no new financial results. The deck reports $90.3 million in cash and cash equivalents as of September 30, 2026, and says up to $95 million in additional funding depends on FDA approval of Anaphylm, with no assurance either facility will become available.

Key points

  • $90.3 million in cash and cash equivalents as of September 30, 2026
  • Potential access to $75 million under a strategic funding agreement with RTW Investments, subject to conditions including FDA approval of Anaphylm
  • An additional $20 million potentially available under the Oaktree Capital Management debt facility, also subject to FDA approval of Anaphylm
  • Anaphylm PDUFA goal date is March 16, 2027, following FDA acceptance of the NDA resubmission

The filing

CompanyAquestive Therapeutics, Inc. (AQST)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:17 PM ET
Accession number0001398733-26-000077

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.